{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:41:49Z","timestamp":1792129309674,"version":"4.4.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.semnuclmed.2011.02.005","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T18:51:37Z","timestamp":1308855097000},"page":"283-299","source":"Crossref","is-referenced-by-count":70,"title":["Positron Emission Tomography Radiopharmaceuticals for Imaging Brain Beta-Amyloid"],"prefix":"10.1053","volume":"41","author":[{"given":"Shankar","family":"Vallabhajosula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2011.02.005_bib1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib2","first-page":"146","article-title":"\u00dcber eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex]","volume":"64","author":"Alzheimer","year":"1907","journal-title":"Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.61.1.59","article-title":"Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials","volume":"61","author":"Grundman","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib5","unstructured":"National Institute on Aging (NIA) and National Institutes of Health (NIH): Alzheimer's Disease: Unraveling the Mystery. NIH Publication Number 08-3792, September 2008"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.005_bib6","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1007\/s00259-007-0697-6","article-title":"Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies","volume":"35","author":"Drzezga","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS\u2013ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib9","series-title":"Handbook of the Neuroscience of Aging","first-page":"275","article-title":"Alzheimer's disease: Neurodegeneration","author":"Cairns","year":"2009"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","article-title":"Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)","volume":"13","author":"Iwatsubo","year":"1995","journal-title":"Neuron"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer's disease","volume":"16","author":"Goedert","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/01.wnl.0000256373.39415.b1","article-title":"Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis","volume":"68","author":"Forman","year":"2007","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.nucmedbio.2007.06.015","article-title":"Impact of amyloid imaging on drug development in Alzheimer's disease","volume":"34","author":"Mathis","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Aca Sci U S A"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archneur.65.3.329","article-title":"Genome-wide association studies in Alzheimer disease","volume":"65","author":"Waring","year":"2008","journal-title":"Arch Neurol"},{"issue":"Suppl","key":"10.1053\/j.semnuclmed.2011.02.005_bib17","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1038\/399a023","article-title":"Translating cell biology into therapeutic advances in Alzheimer's disease","volume":"399","author":"Selkoe","year":"1999","journal-title":"Nature"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib18","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","article-title":"The mini-mental state examination: a comprehensive review","volume":"40","author":"Tombaugh","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2007.43.6.1067341","article-title":"Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein","volume":"43","author":"Marksteiner","year":"2007","journal-title":"Drugs Today"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/alzrt52","article-title":"Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions","volume":"2","author":"Brooks","year":"2010","journal-title":"Alzheimers Res Ther"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jalz.2005.11.002","article-title":"Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia","volume":"2","author":"Jagust","year":"2006","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02988444","article-title":"PET studies in dementia","volume":"17","author":"Herholz","year":"2003","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.semnuclmed.2008.02.006","article-title":"Positron emission tomography scans obtained for the evaluation of cognitive dysfunction","volume":"38","author":"Silverman","year":"2008","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","article-title":"The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core","volume":"6","author":"Jagust","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00259-009-1301-z","article-title":"Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease","volume":"37","author":"N\u00e5gren","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02257652","article-title":"Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography","volume":"2","author":"Nordberg","year":"1990","journal-title":"J Neural Transm"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000106611","article-title":"Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment","volume":"8","author":"Nordberg","year":"1997","journal-title":"Dem Geriatr Cogn Disord"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp.74.1.113","article-title":"Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease","volume":"74","author":"Rinne","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1212\/WNL.52.4.691","article-title":"In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease","volume":"52","author":"Kuhl","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2125.2007.03063.x","article-title":"In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease","volume":"65","author":"Okamura","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/WNL.55.2.205","article-title":"PET shows that striatal dopamine D1 and D2 receptors are differently affected in AD","volume":"55","author":"Kemppainen","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1460-9568.2003.02716.x","article-title":"Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease","volume":"18","author":"Kemppainen","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.50.1.152","article-title":"Striatal uptake of the dopamine reuptake ligand [11C]\u03b2-CFT is reduced in Alzheimer's disease assessed by positron emission tomography","volume":"50","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/JGP.0b013e3180488325","article-title":"A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease","volume":"15","author":"Lanct\u00f4t","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer's disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/01.wnl.0000271377.52421.4a","article-title":"Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment","volume":"69","author":"Truchot","year":"2007","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.neuroimage.2008.01.030","article-title":"A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease","volume":"40","author":"Truchot","year":"2008","journal-title":"Neuroimage"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/brain\/116.3.497","article-title":"Loss of brain 5-HT2 receptors in Alzheimer's disease","volume":"116","author":"Blin","year":"1993","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib40","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1176\/ajp.156.12.1871","article-title":"PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders","volume":"156","author":"Meltzer","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib41","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.neurobiolaging.2007.04.011","article-title":"Reduced 5-HT2A receptor binding in patients with mild cognitive impairment","volume":"29","author":"Hasselbalch","year":"2008","journal-title":"Neurobiol Aging"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.005_bib42","doi-asserted-by":"crossref","first-page":"T45","DOI":"10.1016\/j.neuroimage.2008.04.219","article-title":"Reduced serotonin transporter binding in mesial temporal cortex in Alzheimer's disease: a [11C]DASB PET study","volume":"41","author":"Marner","year":"2008","journal-title":"Neuroimage"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-510X(96)05315-4","article-title":"Opiate receptor avidity and cerebral blood flow in Alzheimer's disease","volume":"148","author":"Cohen","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0306-4522(00)00230-X","article-title":"Histamine H1 receptors in patients with Alzheimer's disease assessed by positron emission tomography","volume":"99","author":"Higuchi","year":"2000","journal-title":"Neuroscience"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12149-007-0094-z","article-title":"Low density of sigma 1 receptors in early Alzheimer's disease","volume":"22","author":"Mishina","year":"2007","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib46","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12149-008-0185-5","article-title":"Adenosine A1 receptors using 8-dicyclopropylmethyl-1-[11C]methyl-3-propylxanthine PET in Alzheimer's disease","volume":"22","author":"Fukumitsu","year":"2008","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib47","first-page":"S6","article-title":"Relationship between the distribution of microglial activation, amyloid plaque load and cerebral glucose metabolism in Alzheimer's disease (AD): an 11 C-PK11195, 18F-FDG and 11C-PIB PET study","volume":"54","author":"Edison","year":"2006","journal-title":"J Am Geriat Society"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib48","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1038\/sj.jcbfm.9600488","article-title":"Evaluation of reference regions for (R)-[11C]PK11195 studies in Alzheimer's disease and mild cognitive impairment","volume":"27","author":"Kropholler","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib49","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2967\/jnumed.108.050583","article-title":"Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease","volume":"49","author":"Tomasi","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/archneurol.2008.511","article-title":"Carbon-11-labeled Pittsburgh compound B and carbon-11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease","volume":"66","author":"Wiley","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.biopsych.2008.04.021","article-title":"Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106","volume":"64","author":"Yasuno","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib52","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2967\/jnumed.107.049619","article-title":"Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET","volume":"49","author":"Esposito","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2967\/jnumed.106.037762","article-title":"Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease","volume":"48","author":"Ng","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib55","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.neuropsychologia.2008.03.020","article-title":"Amyloid imaging in Alzheimer's disease","volume":"46","author":"Nordberg","year":"2008","journal-title":"Neuropsychologia"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.005_bib56","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1007\/s00259-007-0700-2","article-title":"Amyloid plaque imaging in vivo: current achievement and future prospects","volume":"35","author":"Nordberg","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib57","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0891988710363715","article-title":"Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls","volume":"23","author":"Devanand","year":"2010","journal-title":"J Geriatr Psychiatry Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib59","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib60","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh compound B derivative 18 F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease","volume":"50","author":"Nelissen","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid \u03b2 in Alzheimer's disease with 1\u25a1F-BAY94-9172, a novel PET tracer: proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib62","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: a PET agent for A\u03b2 plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadi","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib64","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment","volume":"355","author":"Small","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/bc9901393","article-title":"A\u03b21-40 peptide radiopharmaceuticals for brain amyloid imaging: 111In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections","volume":"11","author":"Kurihara","year":"2000","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib66","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1073\/pnas.0401781101","article-title":"Pauling and Corey's \u03b1-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease","volume":"101","author":"Armen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib67","series-title":"Alzheimer: 100 Years and Beyond","article-title":"Imaging the pathology of Alzheimer's disease: building on a century-old blueprint","author":"Klunk","year":"2006"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib68","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archneur.1985.04060100083029","article-title":"Diagnosis of Alzheimer's disease","volume":"42","author":"Khachaturian","year":"1985","journal-title":"Arch Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib69","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0024-3205(01)01232-2","article-title":"Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain","volume":"69","author":"Klunk","year":"2001","journal-title":"Life Sci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib70","doi-asserted-by":"crossref","first-page":"RC189","DOI":"10.1523\/JNEUROSCI.21-24-j0004.2001","article-title":"Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease","volume":"21","author":"Agdeppa","year":"2001","journal-title":"J Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0960-894X(01)00734-X","article-title":"A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain","volume":"12","author":"Mathis","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib72","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2004.08.004","article-title":"Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease","volume":"1025","author":"Kung","year":"2004","journal-title":"Brain Res"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib74","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2174\/1381612043384772","article-title":"Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain","volume":"10","author":"Mathis","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib75","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","article-title":"The binding of 2-(4\u2032-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component","volume":"23","author":"Klunk","year":"2003","journal-title":"J Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib76","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jlcr.854","article-title":"A rapid one-step radiosynthesis of the \u03b2-amyloid imaging radiotracer N-methyl-[11C]2-(4\u2032-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1)","volume":"47","author":"Wilson","year":"2004","journal-title":"J Label Compd Radiopharm"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.mibio.2003.09.003","article-title":"Iodinated tracers for imaging amyloid plaques in the brain","volume":"5","author":"Kung","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib78","first-page":"584","article-title":"In-vivo imaging of Alzheimer disease \u03b2-amyloid with [11C]SB-13 PET","volume":"12","author":"Verhoeff","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib79","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1523\/JNEUROSCI.4456-03.2004","article-title":"Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain","volume":"24","author":"Okamura","year":"2004","journal-title":"J Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1385\/JMN:24:2:247","article-title":"A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain","volume":"24","author":"Okamura","year":"2004","journal-title":"J Mol Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jlcr.811","article-title":"Novel probes for imaging amyloid-b: F-18 and C-11 labeling of 2-(4-aminostyryl)benzoxazole derivatives","volume":"47","author":"Shimadzu","year":"2004","journal-title":"J Label Compds Radiopharm"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib82","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2967\/jnumed.106.037556","article-title":"2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2[fluoro] ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients","volume":"48","author":"Kudo","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib83","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1471-4159.2008.05861.x","article-title":"AZD2184: a radioligand for sensitive detection of betaamyloid deposits","volume":"108","author":"Johnson","year":"2009","journal-title":"J Neurochem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib84","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00259-009-1182-1","article-title":"Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184","volume":"36","author":"Nyberg","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib85","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1471-4159.2010.06812.x","article-title":"Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand","volume":"114","author":"Jur\u00e9us","year":"2010","journal-title":"J Neurochem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib86","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1074\/jbc.M501285200","article-title":"Delineation of PET imaging agent binding sites on beta-amyloid peptide fibrils","volume":"280","author":"Ye","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib87","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.mibio.2003.09.010","article-title":"Dialkylamino-6-acylmalonnonitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tool in Alzheimer's disease","volume":"5","author":"Agdeppa","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib88","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/WCO.0b013e3283168e1a","article-title":"The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation","volume":"21","author":"Klunk","year":"2008","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.005_bib89","doi-asserted-by":"crossref","first-page":"T113","DOI":"10.1016\/j.neuroimage.2008.04.082","article-title":"Comparison of the binding of 3\u2032-F-PiB and PiB in human brain homogenates","volume":"41","author":"Mathis","year":"2008","journal-title":"Neuroimage"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib90","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2967\/jnumed.108.060756","article-title":"Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging","volume":"50","author":"Koole","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib91","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib92","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1021\/jm050166g","article-title":"F-18 stilbenes as PET imaging agents for detecting \u03b2-amyloid plaques in the brain","volume":"8","author":"Zhang","year":"2005","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nucmedbio.2006.10.003","article-title":"18F-labeled styrylpyridines as PET agents for amyloid plaque imaging","volume":"34","author":"Zhang","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib94","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/bc060239q","article-title":"Fluoro-pegylated (FPEG): imaging agents targeting A\u03b2 aggregates","volume":"18","author":"Stephenson","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib95","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2967\/jnumed.108.055756","article-title":"Radiation dosimetry of {beta}-amyloid tracers 11C-PiB and 18F-BAY94-9172","volume":"50","author":"O'Keefe","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib96","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nucmedbio.2010.02.003","article-title":"Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent","volume":"37","author":"Lin","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib97","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18 F-AV-45 (florbetapir F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of Florbetapir-PET for imaging \u03b2-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib99","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/WNL.38.11.1688","article-title":"A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques","volume":"38","author":"Davies","year":"1988","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib102","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment: beyond controversies, towards a consensus\u2014report of the International Working Group on Mild Cognitive Impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J Intern Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib103","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","article-title":"A\u03b2 deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease","volume":"46","author":"Villemagne","year":"2008","journal-title":"Neuropsychologia"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2011.02.005_bib104","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1007\/s00259-007-0705-x","article-title":"Development and evaluation of compounds for imaging of \u03b2-amyloid plaque by means of positron emission tomography","volume":"35","author":"Henriksen","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.005_bib105","first-page":"1786","article-title":"18F-Florbetaben-PET imaging in the differential diagnosis of dementia","volume":"51","author":"Victor-Villemagne","year":"2010","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2011.02.005_bib106","first-page":"31N","article-title":"SNM highlights lecture: neuroscience","volume":"51","author":"Rowe","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib107","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biopha.2008.02.005","article-title":"Current approaches in the treatment of Alzheimer's disease","volume":"62","author":"Shah","year":"2008","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib108","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","article-title":"Immunotherapy reduces vascular amyloid-beta in PDAPP mice","volume":"28","author":"Schroeter","year":"2008","journal-title":"J Neurosci"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib109","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimmers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2011.02.005_bib110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299811000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299811000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T16:32:25Z","timestamp":1686155545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299811000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0001299811000341"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2011.02.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}